Sahajanand Medical Technologies IPO
Sahajanand Medical Technologies IPO is a Mainboard book-built issue comprising an Offer for Sale (OFS) of equity shares by existing shareholders. The company operates in the medical technology sector, manufacturing cardiovascular and vascular intervention
Sahajanand Medical Technologies IPO Details
Sahajanand Medical Technologies IPO is scheduled to open for subscription on October 15, 2026, and close on October 19, 2026. The basis of allotment is expected to be finalized on October 21, 2026, while the shares are scheduled to be listed on BSE and NSE on October 23, 2026. The issue is structured as an Offer for Sale, meaning the proceeds from the sale of shares will go to the selling shareholders rather than the company.
Sahajanand Medical Technologies IPO Timeline (Tentative)
Sahajanand Medical Technologies IPO is scheduled to open on October 15, 2026, and close on October 19, 2026. The basis of allotment is expected on October 21, followed by the initiation of refunds and credit of shares to successful applicants' Demat accounts on October 22. The shares are scheduled to list on BSE and NSE on October 23, 2026. These dates are subject to the final issue schedule.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Thu, Oct 15, 2026 |
| IPO Close Date | Mon, Oct 19, 2026 |
| Basis of Allotment | Wed, Oct 21, 2026 |
| Initiation of Refunds | Thu, Oct 22, 2026 |
| Credit of Shares to Demat | Thu, Oct 22, 2026 |
| Listing Date | Fri, Oct 23, 2026 |
Sahajanand Medical Technologies IPO Lot Size
The Sahajanand Medical Technologies IPO lot size is 43 shares. At the upper price band of ₹344 per share, one lot requires a minimum investment of ₹14,792. The application amounts for the different investor categories are calculated using the upper price band.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 43 | 14,792 |
| Retail (Max) | 13 | 559 | 1,92,296 |
| S-HNI (Min) | 14 | 602 | 2,07,088 |
| S-HNI (Max) | 66 | 2,838 | 9,76,272 |
| B-HNI (Min) | 67 | 2,881 | 9,91,064 |
Sahajanand Medical Technologies IPO Reservation
Sahajanand Medical Technologies IPO is structured as an Offer for Sale of existing equity shares. The proposed investor reservation is up to 50% for Qualified Institutional Buyers (QIBs), at least 15% for Non-Institutional Investors (NIIs), and at least 35% for Retail Individual Investors (RIIs). The final category-wise share allocation should be confirmed from the applicable offer document and reservation details.
Sahajanand Medical Technologies IPO Subscription
Sahajanand Medical Technologies IPO subscription figures will become available after the bidding process begins on October 15, 2026. The category-wise subscription status will reflect demand from Qualified Institutional Buyers, Non-Institutional Investors and Retail Individual Investors during the subscription period. Final subscription figures should be updated after bidding closes on October 19, 2026.
| Category | Subscription (times) |
|---|---|
| QIB | |
| NII | |
| RII | |
| Total |
About Sahajanand Medical Technologies
Sahajanand Medical Technologies Limited is a medical technology company focused on developing, manufacturing and commercialising medical devices used in cardiovascular and vascular intervention procedures. Its product portfolio includes coronary stents, drug-coated balloons and other devices used by healthcare professionals to treat vascular conditions. The company serves a specialised segment of the healthcare industry, where product quality, clinical performance, regulatory compliance and technological development are important.
The company has developed a presence in the cardiovascular device market through products designed for interventional cardiology and related medical procedures. Its offerings include coronary stents used in the treatment of coronary artery disease. The business also has exposure to structural heart devices and other vascular intervention products, allowing it to participate in multiple areas of specialised medical treatment.
Sahajanand Medical Technologies follows a business model that involves the development, manufacturing and sale of medical devices through healthcare institutions, distributors and other commercial channels. Its products serve domestic and international markets. Since medical devices are subject to regulatory requirements and clinical standards, the company must maintain manufacturing quality, product approvals and compliance with applicable medical device regulations across the markets in which it operates.
The company's performance depends on demand for cardiovascular procedures, its ability to develop and commercialise products, pricing and competition in the medical device industry. It also operates in a sector where research and development, product innovation, manufacturing capabilities and relationships with healthcare providers can influence long-term growth. Investors should assess the company's financial performance, customer and product concentration, regulatory risks and valuation before making an investment decision.
Strengths
- Presence in specialised medical devices: The company operates in the cardiovascular and vascular intervention device market, which requires specialised product development and manufacturing capabilities.
- Established product portfolio: Its products include coronary stents and other medical devices used in interventional procedures.
- Domestic and international business exposure: The company has operations and commercial reach across multiple markets.
- Participation in a specialised healthcare segment: Demand for cardiovascular treatment and interventional procedures provides an underlying market for its products.
- Product development capabilities: Continued development of medical devices can support product expansion and competitiveness.
- Experience in medical device manufacturing: Experience in a regulated industry can support the company's manufacturing and commercial operations, subject to maintaining quality and compliance standards.
Risks to Consider
- Product concentration: A significant share of revenue has been linked to key products, making financial performance sensitive to changes in demand or competition for those products.
- Regulatory risks: Medical devices are subject to regulatory approvals, quality requirements and compliance obligations in different markets.
- Competition: The company competes with domestic and international medical device manufacturers.
- Research and development requirements: Product innovation and maintaining competitiveness may require continuing expenditure on development, testing and regulatory approvals.
- International market exposure: Changes in foreign regulations, currency movements and distribution conditions may affect overseas operations.
- Offer for Sale structure: The IPO proceeds are intended for selling shareholders, and the company will not receive the proceeds to fund its business operations or expansion plans.
Sahajanand Medical Technologies Financials (₹ Cr)
Sahajanand Medical Technologies operates in the medical device industry, with revenue generated from the sale of cardiovascular and other medical products. Its financial performance should be assessed by reviewing revenue growth, profitability, total assets and net worth over multiple reporting periods. The company's FY2023, FY2024 and FY2025 financial statements provide a basis for evaluating its historical performance, while the latest reported financial results should be checked in the applicable offer document.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2023 | 795.50 | 11.93 | 911.63 | 539.21 |
| FY2024 | 901.60 | -7.35 | 970.58 | 526.30 |
| FY2025 | 1,024.88 | 25.15 | 1,094.90 | 545.23 |
KPIs & Valuation
The valuation of Sahajanand Medical Technologies IPO should be assessed using earnings per share, price-to-earnings ratio, return on net worth and other financial indicators disclosed in the final offer documents. The issue price band is ₹327 to ₹344 per share. Since the IPO is an Offer for Sale, investors should also consider the company's profitability, cash flows, product concentration and business risks when assessing the valuation.
Objects of the Issue
Sahajanand Medical Technologies IPO is structured as a 100% Offer for Sale by existing shareholders. The offer involves the sale of equity shares held by the selling shareholders, and the company will not receive the proceeds from these sales. Consequently, the IPO does not provide direct fresh capital to the company through a fresh issue of shares. The principal purpose of the offer is:
- To provide an opportunity for existing shareholders to sell a portion of their shareholding.
- To facilitate the proposed listing of the company's equity shares on BSE and NSE.
- To provide liquidity to eligible selling shareholders through the public market.
Promoters, Lead Managers & Registrar
Sahajanand Medical Technologies IPO has appointed a group of book-running lead managers to manage the public issue. The lead managers include Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited, and Nuvama Wealth Management Limited. MUFG Intime India Private Limited is the registrar to the issue.
Promoters
Lead Managers (BRLM)
Registrar
| Name | MUFG Intime India Private Limited |
|---|---|
| Phone | 022-49186000 |
| sahajanandmedical.ipo@in.mpms.mufg.com | |
| Website | https://in.mpms.mufg.com/ |
Sahajanand Medical Technologies IPO Review
Sahajanand Medical Technologies operates in the specialised medical device industry, with a focus on cardiovascular and vascular intervention products. Its product portfolio includes coronary stents and other devices used in interventional medical procedures. The company's experience in this segment and its access to domestic and international markets are important factors to consider when assessing its business prospects.
The medical technology sector can benefit from increasing healthcare needs and demand for specialised treatment. However, growth depends on the company's ability to maintain product quality, meet regulatory requirements, compete with other device manufacturers and develop products that meet the requirements of healthcare professionals. Product concentration and competition can influence revenue growth and profitability.
An important feature of this IPO is its Offer for Sale structure. Since the issue involves the sale of existing shares, the proceeds will go to the selling shareholders rather than the company. Investors should therefore evaluate the company's financial performance, cash flows, profitability, business concentration and valuation rather than treating the IPO as a capital-raising issue for business expansion.
The final investment assessment should consider the published price band, earnings per share, valuation multiples, risk factors and latest financial information in the offer documents. Grey Market Premium, if reported, is unofficial and should not be treated as a reliable prediction of listing performance. Investors should review the final offer document before making an investment decision.
How to Apply
Sahajanand Medical Technologies IPO applications can generally be submitted through ASBA or UPI-enabled IPO application facilities, subject to the eligibility and procedures of the investor's bank or broker. Investors should confirm the final issue dates and application details before submitting an application.
Through UPI
-
Log in to your stockbroker's app or website.
-
Open the IPO section.
-
Select Sahajanand Medical Technologies IPO.
-
Enter the number of lots you want to apply for.
-
Enter your bid price or select the cut-off option if available and applicable.
-
Provide your valid UPI ID.
-
Submit the IPO application.
-
Open your UPI app when the mandate request arrives.
-
Approve the mandate using your UPI PIN before the deadline.
-
The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors should review the official offer documents for detailed information about Sahajanand Medical Technologies, its financial performance, risk factors, selling shareholders, IPO structure and other material disclosures. The Draft Red Herring Prospectus and subsequent offer documents should be used to verify the final issue details before making an investment decision. The official investor section provides access to the company's IPO disclosures and financial information.
Last updated Oct 12, 2026.